Pharma News, 2022

AstraZeneca topped off a very busy week with its first-quarter financial report, citing a total of $11.390 billion in revenue, a whopping increase of 60%.  ...

The FDA and the European Commission have granted AviadoBio Orphan Drug designations for its investigational gene therapy, AVB-101, for the treatment of patients with frontotemporal dementia (FTD). ...

The FDA has approved Epsolay cream for the treatment of inflammatory lesions of rosacea, Sol-Gel Technologies announced in a press release.

The U.S. Food and Drug Administration (FDA) approved VIVJOA™ (oteseconazole capsules), an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in female...

The European Commission has granted marketing authorization to Cara Therapeutics’ and Vifor Pharma’s Kapruvia (difelikefalin) for the treatment of patients with moderate-to-severe pruritus asso...

LianBio said Friday that Bristol Myers Squibb got U.S. Food and Drug Administration approval for Camzyos mavacamten capsules for the treatment of adults with symptomatic class II-III obstructive hy...

The US Food and Drug Administration (FDA) has granted Fast Track Designation for SQZ Biotechnologies’ lead cell therapy candidate, SQZ-PBMC-HPV, for treating HPV16+ advanced or metastatic solid t...

C. Michael White, Professor of Pharmacy Practice, University of Connecticut: Many over-the-counter dietary supplement products — especially those used for sexual enhancement and weight loss — a...

The FDA has granted AstraZeneca’s and Daiichi Sankyo’s antibody drug conjugate Enhertu (trastuzumab deruxtecan) a fifth Breakthrough Therapy designation for patients with unresectable or metas...

The European Commission has granted a marketing authorization for Pfizer’s and Biohaven Pharmaceutical’s oral migraine drug Vydura (rimegepant).

Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate vgAAV-based therapeutic candidates.

New research published in Neurology and Therapy suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab (BAN2401) is estimated to slow the rate of disease progression in patie...